Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Prince of Songkla University

Status: Enrolling

Conditions: Glaucoma, Neovascular; Vascular Endothelial Growth Factor Overexpression

Treatments: Procedure: Intracameral injection; Procedure: Intravitreal injection

Study type: Interventional

Funder types: Other

Identifiers

NCT03648814

REC6100321

Details and patient eligibility

About

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Full description

The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosis of neovascular glaucoma
2. The patients having IOP > 21 mmHg, having the indication for trabeculectomy
3. The patients' age of at least 18-year-old
4. The patients having visual potential at least hand motion.
5. Present of NVI or NVA.
6. Willing and able to provide informed consent to participate in the study
7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

Exclusion criteria

1. One eye patient
2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
3. Cannot obtain endothelial cell count.
4. History of bevacizumab or fluorescence dye allergy.
5. Active infectious ocular disease including endophthalmitis and corneal ulcer
6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
7. Has or planning to be pregnant or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

Intracameral injection

Experimental group

Description:

Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection

Treatment:

Procedure: Intracameral injection

Intravitreal injection

Experimental group

Description:

Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection

Treatment:

Procedure: Intravitreal injection